Trial Profile
RECURENT NEUROBLASTOMA AND EWING´S SARCOMA: TREOSULPHAN BASED HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBSC SUPPORT
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Melphalan (Primary) ; Treosulfan (Primary)
- Indications Ewing's sarcoma; Neuroblastoma
- Focus Therapeutic Use
- Acronyms ReNETA
- 24 Jan 2024 Status changed from recruiting to discontinued.
- 24 Jan 2024 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.
- 28 May 2020 This trial has been discontinued in Czech Republic, according to European Clinical Trials Database record.